Erin Vaughan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Erin Vaughan has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Gilbert
Renal Medicine, Kidney Centre, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia
1 shared publication - Bree Shi
Faculty of Medicine and Health, University of Sydney, Camperdown, NSW 2050, Australia
1 shared publication - Charlotte Cornwell
Transplantation Services , Royal Prince Alfred Hospital , Camperdown , New South Wales , Australia , nsw.gov.au
1 shared publication - Griffith Boord Perkins
Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, Australia
1 shared publication - Huiling Wu
Faculty of Medicine and Health, University of Sydney, Camperdown, NSW 2050, Australia
1 shared publication - Jerome Martin Laurence
Institute of Academic Surgery (IAS), Royal Prince Alfred Hospital Sydney NSW Australia
1 shared publication
Latest Publications
- Open Access
The Role of the Gut Microbiota and Uraemic Toxins in Vaccine Responsiveness Among People Receiving Maintenance Haemodialysis
Background: Patients with kidney failure requiring dialysis experience a high burden of vaccine-preventable diseases, and vaccine hypo-responsiveness is a key contributor. Uraemic toxins and gut dysbiosis are potential causes of hypo-responsiveness. Aim: This study aimed to determine whether uraemic toxin concentrations or gut dysbiosis are associated with vaccine response in haemodialysis patients. Methods: This was a single centre, observational cohort study of maintenance dialysis patients receiving a conventional 2-dose primary COVID-19 vaccination course. Demographic, clinical and vaccination data were collected from the eMR. Vaccine response (Elecsys Anti-SARS-CoV-2 immunoassay), serum uraemic toxin concentrations (indoxyl sulphate, p-cresyl sulphate, and trimethylamine N-oxide by liquid chromatography), and stool microbiome (16S rRNA gene sequencing) were measured 8 weeks after the second dose of vaccine. Results: Forty participants (43% female, mean age 66 years; 59% Caucasian) were included, 70% of whom were classified as a vaccine responder. Antibiotic exposure, prednisolone use and lymphopenia were significantly associated with hypo-responsiveness. Microbiome profiling identified differences in beta diversity between responders and non-responders, positively correlated with short-chain fatty acid producers (Parabacteriodes) and negatively with pathobionts (Escherichia/Shigella). Differential abundance analysis identified lower levels of Tyzzerella, Gemmiger, and Hungatella and higher levels of Turicibacter in vaccine responders. Total uraemic toxin burden and individual toxin concentrations did not differ between responders and hypo-responders (all p > 0.05). Stratification by low versus high/very high toxin burden groupings was not associated with response (p > 0.99). Conclusions: Differences in gut microbial composition were observed between vaccine responder groups, while uraemic toxin concentrations were not associated with vaccine responsiveness. These findings suggest gut microbiota composition may contribute to vaccine hypo-responsiveness in individuals receiving dialysis and warrant further investigation in larger mechanistic studies.
Open AccessThe Role of the Gut Microbiota and Uraemic Toxins in Vaccine Responsiveness Among People Receiving Maintenance Haemodialysis
Background: Patients with kidney failure requiring dialysis experience a high burden of vaccine-preventable diseases, and vaccine hypo-responsiveness is a key contributor. Uraemic toxins and gut dysbiosis are potential causes of hypo-responsiveness. Aim: This study aimed to determine whether uraemic toxin concentrations or gut dysbiosis are associated with vaccine response in haemodialysis patients. Methods: This was a single centre, observational cohort study of maintenance dialysis patients receiving a conventional 2-dose primary COVID-19 vaccination course. Demographic, clinical and vaccination data were collected from the eMR. Vaccine response (Elecsys Anti-SARS-CoV-2 immunoassay), serum uraemic toxin concentrations (indoxyl sulphate, p-cresyl sulphate, and trimethylamine N-oxide by liquid chromatography), and stool microbiome (16S rRNA gene sequencing) were measured 8 weeks after the second dose of vaccine. Results: Forty participants (43% female, mean age 66 years; 59% Caucasian) were included, 70% of whom were classified as a vaccine responder. Antibiotic exposure, prednisolone use and lymphopenia were significantly associated with hypo-responsiveness. Microbiome profiling identified differences in beta diversity between responders and non-responders, positively correlated with short-chain fatty acid producers (Parabacteriodes) and negatively with pathobionts (Escherichia/Shigella). Differential abundance analysis identified lower levels of Tyzzerella, Gemmiger, and Hungatella and higher levels of Turicibacter in vaccine responders. Total uraemic toxin burden and individual toxin concentrations did not differ between responders and hypo-responders (all p > 0.05). Stratification by low versus high/very high toxin burden groupings was not associated with response (p > 0.99). Conclusions: Differences in gut microbial composition were observed between vaccine responder groups, while uraemic toxin concentrations were not associated with vaccine responsiveness. These findings suggest gut microbiota composition may contribute to vaccine hypo-responsiveness in individuals receiving dialysis and warrant further investigation in larger mechanistic studies.
- 16 March 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (4) , 538-540
When “Low-Grade” Is No Longer Low Risk in IgA Nephropathy
- 16 March 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (4) , 538-540
When “Low-Grade” Is No Longer Low Risk in IgA Nephropathy
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Transplantation
- Vol. 2026 (1) , 5753967
Assessing Surgical Feasibility of Peritoneal Dialysis Following Liver–Lung Transplantation: A Case Report
Kidney failure is a common complication in recipients of nonkidney solid organ transplants (NKSOT), often stemming from prolonged calcineurin inhibitor (CNI) exposure or perioperative insults. Although haemodialysis (HD) remains the predominant renal replacement therapy (RRT), peritoneal dialysis (PD) offers advantages such as better quality of life, haemodynamic stability and preservation of residual renal function. Concerns about infection risk, technical feasibility and respiratory complications have curtailed its broader use. We present the first reported case of successful PD in a liver and double‐lung transplant recipient. The patient, a 30‐year‐old male with cystic fibrosis, extensive abdominal surgery and immunosuppression, was initially deemed unsuitable for PD due to surgical complexity and potential complications in a transplant recipient. A multidisciplinary team (MDT) review at our liver and kidney transplant specialist centre ultimately supported PD based on clinical suitability and lifestyle preferences. Laparoscopic catheter insertion was achieved despite significant intra‐abdominal adhesions, and the patient remained on PD for 18 months without complications. This case underscores that with meticulous surgical planning and MDT input, PD can be a safe and viable option in complex NKSOT recipients. It challenges prevailing biases against PD in this population and suggests that prior transplantation should not preclude its consideration.
- 1 January 2026
- Published by Wiley in Case Reports in Transplantation
- Vol. 2026 (1) , 5753967
Open AccessAssessing Surgical Feasibility of Peritoneal Dialysis Following Liver–Lung Transplantation: A Case Report
Kidney failure is a common complication in recipients of nonkidney solid organ transplants (NKSOT), often stemming from prolonged calcineurin inhibitor (CNI) exposure or perioperative insults. Although haemodialysis (HD) remains the predominant renal replacement therapy (RRT), peritoneal dialysis (PD) offers advantages such as better quality of life, haemodynamic stability and preservation of residual renal function. Concerns about infection risk, technical feasibility and respiratory complications have curtailed its broader use. We present the first reported case of successful PD in a liver and double‐lung transplant recipient. The patient, a 30‐year‐old male with cystic fibrosis, extensive abdominal surgery and immunosuppression, was initially deemed unsuitable for PD due to surgical complexity and potential complications in a transplant recipient. A multidisciplinary team (MDT) review at our liver and kidney transplant specialist centre ultimately supported PD based on clinical suitability and lifestyle preferences. Laparoscopic catheter insertion was achieved despite significant intra‐abdominal adhesions, and the patient remained on PD for 18 months without complications. This case underscores that with meticulous surgical planning and MDT input, PD can be a safe and viable option in complex NKSOT recipients. It challenges prevailing biases against PD in this population and suggests that prior transplantation should not preclude its consideration.